Notably, analysis of 16,300 gynecologic cancer samples revealed significantly lower expression of PD-1/PD-L1, MSI-high (MSI-H), or high TMB in ovarian cancers compared to uterine cervical and corpus cancers (8). This evidence concerns the gene PDCD1 and ovarian cancer.